Contact:
4008465777
-
About Us
News & Events
-
02-13
Tonghua Dongbao's Dual GLP-1/GIP Receptor Agonist (THDBH120 Injection) Meets Primary Endpoint in Phase Ib Trial for Weight Loss, Reducing Weight by 9.36% in Six Weeks
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), completed a Phase Ib pivotal clinical...
-
01-22
Tonghua Dongbao Receives Marketing Approval for Etoricoxib Tablets, Advancing Its Entry into the Gout Market
Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") has recently received a Drug Registration Certificate for etoricoxib tablets from the National Medical Products Administra...
-
08-01
Tonghua Dongbao: First Patient Dosed in Phase III Clinical Trial of Semaglutide Injection (THDB0225 Injection)
In May 2024, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as "Tonghua Dongbao" or "the Company") signed the Commercialization Licensing and Marketing Authorization Holder (MAH) Ag...
-
07-26
Tonghua Dongbao: First Subject Dosed in Phase Ib Clinical Trial of Dual GLP-1/GIP Receptor Agonist (THDBH120 Injection) for weight loss Indications
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company"), received the notice of approval from the Center for Drug E...
-
07-05
International Milestone | Tonghua Dongbao Passes EMA Pre-approval GMP Inspection
Tonghua Dongbao Pharmaceutical Co., Ltd. ( "the Company" or "Tonghua Dongbao") underwent an on-site inspection by the European Medicines Agency (EMA) in April 2024. Recently, the Company received a no...
-
06-21
Tonghua Dongbao: First Patient Dosed in Phase Ib Clinical Trial of Dual GLP-1/GIP Receptor Agonist (THDBH120 Injection) for Diabetes Indications
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company"), received the notice of approval from the Center for Drug E...